

CONTENTS

LIST OF TABLES

LIST OF FIGURES

GLOSSARY OF ABBREVIATIONS

1. SOMMARIO/SUMMARY.....	I-III
2. INTRODUCTION.....	1
2.1 <i>Integrins</i>	1
2.1.1 Integrins biology.....	1
2.1.2 Integrins in angiogenesis and lymphangiogenesis.....	4
2.1.2.1 <i>Introductory overview on angiogenesis and lymphangiogenesis</i>	4
2.1.2.2 <i>The αv integrins</i>	6
2.1.2.3 <i>Fibronectin-binding integrins</i>	7
2.1.2.4 <i>Laminin-binding integrins</i>	7
2.1.2.5 <i>Integrins in lymphangiogenesis</i>	8
2.1.3 Integrins in cancer.....	8
2.1.3.1 <i>Integrins regulate cell survival and apoptosis</i>	8
2.1.3.2 <i>Integrins cross-talk with growth factors, cytokines and their receptors</i>	11
2.1.4 Potential applications of integrins targeting.....	14
2.1.4.1 <i>Cancer therapy</i>	14
2.1.4.2 <i>Cancer drug delivery and imaging</i>	19
2.2 <i>In-house synthesized RGD integrin ligands</i>	22
2.2.1 Azabicycloalkane amino acids scaffolds and their biological role.....	22
2.2.2 Cyclic RGD-containing functionalized azabicycloalkane peptides.....	25
2.2.3 Fluorescein-conjugated cyclic RGD peptidomimetics.....	26
2.2.4 Cyclic-RGD functionalized gold nanoparticles.....	26
3. AIM OF THE WORK.....	28
4. MATERIALS AND METHODS.....	29
4.1 <i>Cell Biology</i>	29
4.1.1 General procedures.....	29
4.1.2. Culture of adherent cell lines.....	29
4.1.3 Storage and recovery of eukaryotic cells from liquid nitrogen.....	29
4.2 <i>Cell-free procedures</i>	30
4.2.1 Human vitronectin biotinylation.....	30
4.2.2 Solid-phase receptor-binding assay.....	30

4.3 Biological assays	31
4.3.1 Immunofluorescence on adherent cells.....	31
4.3.2 Flow cytometry.....	31
4.3.3 Adhesion assay.....	32
4.3.4 Wound healing assay.....	32
4.3.5 Actin remodelling test after Compound 31 treatment.....	33
4.3.6 Treatment of cells with fluorescein-conjugated compounds and cyclic RGD functionalized gold nanoparticles.....	33
4.3.7 Antibodies.....	33
5. RESULTS	34
5.1 Surface antigen characterization of the panel of human cell lines	34
5.1.1 Introductory remarks.....	34
5.1.2 Flow cytometry.....	34
5.1.3 Immunofluorescence.....	35
5.2 Cell-free screening of test compounds	38
5.2.1 Introductory remarks.....	38
5.2.2 Compounds 31, 13 and 15 show a good binding affinity for integrin $\alpha v \beta 3$..	38
5.3 The biological activity of Compound 31 on human endothelial cells suggests its possible use as anti-angiogenic compound	39
5.3.1 Introductory remarks.....	39
5.3.2 Compound 31 impairs endothelial cells adhesion to either vitronectin or fibronectin.....	39
5.3.3 Compound 31 displays <i>in vitro</i> anti-migratory activity on endothelial cells..	40
5.4 Biological activity of Compound 31 on human cancer cells	43
5.4.1 Introductory remarks.....	43
5.4.2 Compound 31 impairs cell adhesion to either vitronectin or fibronectin in human cancer cells.....	43
5.4.3 Compound 31 displays <i>in vitro</i> anti-migratory activity on multiforme glioblastoma cells.....	46
5.4.4 Compound 31 drives actin remodelling in multiforme glioblastoma cells.....	47
5.5 Fluorescein-conjugated compounds are good imaging vehicles in vitro	50
5.5.1 Introductory remarks.....	50
5.5.2 Compounds 13 and 15 positively stained integrin $\alpha v \beta 3$ expressing cells.....	50
5.6 Gold nanoparticles conjugated with cyclic RGD and fluorescein display a highly specific imaging activity in vitro	52
5.6.1 Introductory remarks.....	52
5.6.2 Compound DA425 positively stained prostate cancer cells.....	52

6. DISCUSSION.....	54
7. CONCLUSIONS.....	59
BIBLIOGRAPHY.....	I-IV

APPENDIX I

SCIENTIFIC PRODUCTS

ACKNOWLEDGEMENTS

